What is a stock summary page? Click here for an overview.
Business Description
Caribou Biosciences Inc
NAICS : 541713
SIC : 2833
ISIN : US1420381089
Share Class Description:
CRBU: Ordinary SharesDescription
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.91 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.9 | |||||
| Beneish M-Score | -2.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.4 | |||||
| 3-Year EBITDA Growth Rate | 4.7 | |||||
| 3-Year EPS without NRI Growth Rate | 8.4 | |||||
| 3-Year FCF Growth Rate | -12.5 | |||||
| 3-Year Book Growth Rate | -24.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -20.66 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 79.79 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.35 | |||||
| 9-Day RSI | 43.43 | |||||
| 14-Day RSI | 39.08 | |||||
| 3-1 Month Momentum % | -24.26 | |||||
| 6-1 Month Momentum % | -33.33 | |||||
| 12-1 Month Momentum % | -75.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.16 | |||||
| Quick Ratio | 7.16 | |||||
| Cash Ratio | 6.84 | |||||
| Days Sales Outstanding | 12.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.3 | |||||
| Shareholder Yield % | -15.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1667.16 | |||||
| Net Margin % | -1491.95 | |||||
| FCF Margin % | -1447.92 | |||||
| ROE % | -47.9 | |||||
| ROA % | -39.88 | |||||
| ROIC % | -148.2 | |||||
| 3-Year ROIIC % | -226.54 | |||||
| ROC (Joel Greenblatt) % | -413.16 | |||||
| ROCE % | -48.48 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.97 | |||||
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 0.52 | |||||
| EV-to-EBITDA | 0.53 | |||||
| EV-to-Revenue | -8.64 | |||||
| EV-to-Forward-Revenue | 1.31 | |||||
| EV-to-FCF | 0.62 | |||||
| Price-to-GF-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 192.31 | |||||
| FCF Yield % | -152.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRBU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Caribou Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.994 | ||
| EPS (TTM) ($) | -1.65 | ||
| Beta | 2.36 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 79.19 | ||
| 14-Day RSI | 39.08 | ||
| 14-Day ATR ($) | 0.08421 | ||
| 20-Day SMA ($) | 1.09408 | ||
| 12-1 Month Momentum % | -75.53 | ||
| 52-Week Range ($) | 0.95 - 5.615 | ||
| Shares Outstanding (Mil) | 93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caribou Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caribou Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Caribou Biosciences Inc Frequently Asked Questions
What is Caribou Biosciences Inc(CRBU)'s stock price today?
The current price of CRBU is $1.02. The 52 week high of CRBU is $5.62 and 52 week low is $0.95.
When is next earnings date of Caribou Biosciences Inc(CRBU)?
The next earnings date of Caribou Biosciences Inc(CRBU) is 2025-05-07 Est..
Does Caribou Biosciences Inc(CRBU) pay dividends? If so, how much?
Caribou Biosciences Inc(CRBU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers